RxDoctor Payments Data

Stephen Ashe, MD

Ophthalmology · Memphis, TNNPI 1639532823

Payments from drug & device makers

$836in general payments, 2019–2025

Across 24 payments — averaging $34.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$190
  • Bausch & Lomb Americas Inc.$169
  • Amgen$124
  • Oyster Point Pharma, Inc.$121
  • AbbVie$76
  • UCB, Inc.$34
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836 in reported general payments places this provider in the 35th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$173,401
Medicare patients
382
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$63,034
Prednisolone Acetate842$25,931
ProlensaBromfenac Sodium35$12,601
CombiganBrimonidine Tartrate/Timolol38$10,259
XiidraLifitegrast14$9,411
Bromfenac Sodium43$8,403
MoxifloxacinMoxifloxacin Hcl314$7,757
Difluprednate42$4,037
ValacyclovirValacyclovir Hcl64$3,090
Brimonidine Tartrate32$2,947
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,160
Loteprednol Etabonate22$2,062
Fluorometholone26$1,782
Atropine Sulfate33$1,241
Doxycycline Hyclate91$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$76$73,293110 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$21$14,66357 claims
Bausch & Lomb Americas Inc.Xiidra$169$9,41114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →